Publications by authors named "Christopher M Yea"

Claim this Profile
L
Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension.
Henriette Farkas, John Anderson, Laurence Bouillet, Teresa Caballero, Mauro Cancian, Christopher M Yea

J Allergy Clin Immunol Pract· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S.
Jonathan A Bernstein, Emel Aygören-Pürsün, Mauro Cancian, Danny M Cohn, Timothy Craig, Christopher M Yea

Clin Transl Allergy· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review.
Hilary J Longhurst, Mauro Cancian, Vesna Grivcheva-Panovska, Majed Koleilat, Markus Magerl, Christopher M Yea

Clin Rev Allergy Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.
Marc A Riedl, Henriette Farkas, Emel Aygören-Pürsün, Fotis Psarros, Daniel F Soteres, Christopher M Yea

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat.
Danny M Cohn, Emel Aygören-Pürsün, Jonathan A Bernstein, Henriette Farkas, William R Lumry, Christopher M Yea

Clin Transl Allergy· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
Emel Aygören-Pürsün, Andrea Zanichelli, Danny M Cohn, Mauro Cancian, Roman Hakl, Christopher M Yea

Lancet· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
Edward J Duckworth, Nivetha Murugesan, Lily Li, Louise J Rushbrooke, Daniel K Lee, Christopher M Yea

Clin Exp Allergy· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results.
Andreas Maetzel, Michael D Smith, Edward J Duckworth, Sally L Hampton, Gian Marco De Donatis, Christopher M Yea

J Allergy Clin Immunol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.
Christopher M Yea, Christine E Allan, Doreen M Ashworth, James Barnett, Andy J Baxter

J Med Chem· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-peptide oxytocin agonists.
Gary R W Pitt, Andrzej R Batt, Robert M Haigh, Andrew M Penson, Peter A Robson, Christopher M Yea

Bioorg Med Chem Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis